Integra Financial Statements From 2010 to 2024

IART Stock  USD 29.38  0.40  1.38%   
Integra LifeSciences financial statements provide useful quarterly and yearly information to potential Integra LifeSciences Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Integra LifeSciences financial statements helps investors assess Integra LifeSciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Integra LifeSciences' valuation are summarized below:
Gross Profit
982 M
Profit Margin
0.0439
Market Capitalization
2.3 B
Enterprise Value Revenue
2.5628
Revenue
1.5 B
There are currently one hundred twenty fundamental trends for Integra LifeSciences that can be evaluated and compared over time across competitors. All traders should confirm Integra LifeSciences' regular fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 1 B in 2024. Enterprise Value is likely to gain to about 442.9 M in 2024

Integra LifeSciences Total Revenue

1.62 Billion

Check Integra LifeSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Integra main balance sheet or income statement drivers, such as Depreciation And Amortization of 129.7 M, Interest Expense of 75.4 M or Total Revenue of 1.6 B, as well as many exotic indicators such as Price To Sales Ratio of 4.18, Dividend Yield of 0.43 or PTB Ratio of 3.53. Integra financial statements analysis is a perfect complement when working with Integra LifeSciences Valuation or Volatility modules.
  
This module can also supplement Integra LifeSciences' financial leverage analysis and stock options assessment as well as various Integra LifeSciences Technical models . Check out the analysis of Integra LifeSciences Correlation against competitors.

Integra LifeSciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsB3.8 B2.5 B
Slightly volatile
Other Current Liabilities92.2 M176.3 M129.8 M
Slightly volatile
Total Current Liabilities158.9 M307 M212.6 M
Slightly volatile
Total Stockholder Equity1.7 B1.6 B1.1 B
Slightly volatile
Property Plant And Equipment Net521.2 M496.4 M293.5 M
Slightly volatile
Accounts Payable96.9 M92.3 M60.3 M
Slightly volatile
Cash290.2 M276.4 M204.3 M
Slightly volatile
Non Current Assets Total2.9 B2.7 B1.8 B
Slightly volatile
Cash And Short Term Investments324.6 M309.1 M208.8 M
Slightly volatile
Net Receivables272.3 M259.3 M187.4 M
Slightly volatile
Common Stock Shares Outstanding67.2 M80.3 M71 M
Slightly volatile
Liabilities And Stockholders EquityB3.8 B2.5 B
Slightly volatile
Non Current Liabilities TotalB1.9 B1.2 B
Slightly volatile
Inventory409.1 M389.6 M257.8 M
Slightly volatile
Other Current Assets51.5 M100 M71.2 M
Slightly volatile
Other Stockholder Equity483.4 M655.2 M644 M
Slightly volatile
Total Liabilities2.3 B2.2 B1.4 B
Slightly volatile
Property Plant And Equipment Gross907 M863.8 M386.7 M
Slightly volatile
Total Current Assets1.1 B1.1 B738.6 M
Slightly volatile
Intangible Assets1.1 B1.1 B732.9 M
Slightly volatile
Short and Long Term Debt Total1.8 B1.7 B1.1 B
Slightly volatile
Common Stock Total Equity528.7 KM655.4 K
Slightly volatile
Short Term Debt28.3 M29.8 M77.7 M
Very volatile
Common Stock547.5 K909 K647.9 K
Slightly volatile
Other Liabilities243.7 M232.1 M116.2 M
Slightly volatile
Other Assets69 M72.6 M292.1 M
Pretty Stable
Long Term Debt749.7 M1.5 B930.9 M
Slightly volatile
Property Plant Equipment375.9 M358 M247.3 M
Slightly volatile
Current Deferred Revenue5.3 M8.5 M5.5 M
Slightly volatile
Good Will1.1 B1.1 B681.5 M
Slightly volatile
Retained Earnings Total Equity1.1 BB465.1 M
Slightly volatile
Long Term Debt TotalB1.5 B968.7 M
Slightly volatile
Capital SurpluseB1.5 B977 M
Slightly volatile
Non Current Liabilities Other150.3 M199.9 M137.6 M
Slightly volatile
Deferred Long Term Asset Charges8.1 M6.2 M9.2 M
Slightly volatile
Short and Long Term Debt13.8 M14.5 M72.5 M
Very volatile
Long Term Investments3.5 M6.2 M3.4 M
Slightly volatile
Net Invested Capital3.3 B3.1 B2.9 B
Slightly volatile
Net Working Capital747.1 M751.1 M587.6 M
Slightly volatile
Capital Stock984.5 K909 K893 K
Slightly volatile
Capital Lease Obligations147.4 M182.1 M120.3 M
Slightly volatile

Integra LifeSciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization129.7 M123.5 M37.6 M
Slightly volatile
Total Revenue1.6 B1.5 B1.1 B
Slightly volatile
Gross Profit458 M888.4 M666.7 M
Slightly volatile
Other Operating Expenses1.4 B1.4 BB
Slightly volatile
EBIT182.8 M174.1 M116.1 M
Slightly volatile
Research Development44.7 M62.7 M61.4 M
Slightly volatile
EBITDA312.5 M297.6 M153.7 M
Slightly volatile
Cost Of Revenue685.8 M653.2 M439.8 M
Slightly volatile
Total Operating Expenses383.8 M714.3 M561.6 M
Slightly volatile
Selling General Administrative339.5 M656.6 M486.6 M
Slightly volatile
Non Recurring61.4 M74.7 M60.5 M
Slightly volatile
Interest Income10.1 M17.2 M14 M
Slightly volatile
Reconciled Depreciation107.5 M123.5 M94.3 M
Pretty Stable

Integra LifeSciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow479.5 M456.7 M207 M
Slightly volatile
Depreciation129.7 M123.5 M84 M
Slightly volatile
Capital Expenditures35.1 M66.9 M53.2 M
Slightly volatile
End Period Cash Flow290.2 M276.4 M204.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.182.26253.4642
Pretty Stable
Dividend Yield0.430.410.4223
Slightly volatile
PTB Ratio3.532.19663.2705
Pretty Stable
Days Sales Outstanding68.9461.401159.9454
Slightly volatile
Book Value Per Share20.8219.826513.9218
Slightly volatile
Invested Capital0.660.9540.9384
Pretty Stable
PB Ratio3.532.19663.2705
Pretty Stable
EV To Sales4.573.17414.1024
Pretty Stable
Inventory Turnover1.941.67651.771
Very volatile
Days Of Inventory On Hand170218212
Slightly volatile
Payables Turnover10.647.07478.6135
Slightly volatile
Sales General And Administrative To Revenue0.570.540.5003
Pretty Stable
Research And Ddevelopement To Revenue0.03860.04070.0861
Slightly volatile
Cash Per Share4.053.85942.7017
Slightly volatile
Days Payables Outstanding32.1651.592246.0843
Pretty Stable
Intangibles To Total Assets0.340.56140.5011
Slightly volatile
Current Ratio5.533.44663.7716
Pretty Stable
Receivables Turnover4.745.94456.1394
Slightly volatile
Graham Number20.419.424716.0552
Slightly volatile
Shareholders Equity Per Share20.8219.826513.9218
Slightly volatile
Debt To Equity0.660.9540.9384
Pretty Stable
Revenue Per Share20.2119.248215.153
Slightly volatile
Interest Debt Per Share20.819.811314.4493
Slightly volatile
Debt To Assets0.290.40050.4006
Pretty Stable
Enterprise Value Over EBITDA15.8916.442727.7797
Pretty Stable
Short Term Coverage Ratios3.284.69418.7424
Slightly volatile
Operating Cycle219279267
Very volatile
Price Book Value Ratio3.532.19663.2705
Pretty Stable
Days Of Payables Outstanding32.1651.592246.0843
Pretty Stable
Ebt Per Ebit0.440.46571.2707
Slightly volatile
Company Equity Multiplier1.582.38182.1935
Pretty Stable
Long Term Debt To Capitalization0.330.48330.4566
Pretty Stable
Total Debt To Capitalization0.330.48820.4644
Pretty Stable
Debt Equity Ratio0.660.9540.9384
Pretty Stable
Quick Ratio2.851.85171.9793
Very volatile
Cash Ratio1.470.90041.0171
Very volatile
Cash Conversion Cycle257228226
Pretty Stable
Days Of Inventory Outstanding170218212
Slightly volatile
Days Of Sales Outstanding68.9461.401159.9454
Slightly volatile
Cash Flow Coverage Ratios0.08780.09240.1502
Slightly volatile
Price To Book Ratio3.532.19663.2705
Pretty Stable
Fixed Asset Turnover6.043.10564.1324
Very volatile
Enterprise Value Multiple15.8916.442727.7797
Pretty Stable
Debt Ratio0.290.40050.4006
Pretty Stable
Cash Flow To Debt Ratio0.08780.09240.1502
Slightly volatile
Price Sales Ratio4.182.26253.4642
Pretty Stable
Asset Turnover0.590.40760.5162
Slightly volatile
Gross Profit Margin0.50.57630.6133
Slightly volatile
Price Fair Value3.532.19663.2705
Pretty Stable

Integra LifeSciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapB963.6 M996.9 M
Slightly volatile
Enterprise Value442.9 M421.8 M440.4 M
Slightly volatile

Integra Fundamental Market Drivers

Forward Price Earnings9.9404
Cash And Short Term Investments309.1 M

Integra Upcoming Events

28th of February 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Integra LifeSciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Integra LifeSciences income statement, its balance sheet, and the statement of cash flows. Integra LifeSciences investors use historical funamental indicators, such as Integra LifeSciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Integra LifeSciences investors may use each financial statement separately, they are all related. The changes in Integra LifeSciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Integra LifeSciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Integra LifeSciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Integra LifeSciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue8.5 M5.3 M
Total Revenue1.5 B1.6 B
Cost Of Revenue653.2 M685.8 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.54  0.57 
Research And Ddevelopement To Revenue 0.04  0.04 
Capex To Revenue(0.04)(0.05)
Revenue Per Share 19.25  20.21 
Ebit Per Revenue 0.11  0.12 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Integra LifeSciences is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Integra Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Integra Lifesciences Holdings Stock. Highlighted below are key reports to facilitate an investment decision about Integra Lifesciences Holdings Stock:
Check out the analysis of Integra LifeSciences Correlation against competitors.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Integra Stock analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Transaction History
View history of all your transactions and understand their impact on performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Is Integra LifeSciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integra LifeSciences. If investors know Integra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integra LifeSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.60)
Earnings Share
0.84
Revenue Per Share
19.248
Quarterly Revenue Growth
(0)
Return On Assets
0.0424
The market value of Integra LifeSciences is measured differently than its book value, which is the value of Integra that is recorded on the company's balance sheet. Investors also form their own opinion of Integra LifeSciences' value that differs from its market value or its book value, called intrinsic value, which is Integra LifeSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integra LifeSciences' market value can be influenced by many factors that don't directly affect Integra LifeSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integra LifeSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Integra LifeSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integra LifeSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.